Posted by Michael Wonder on 25 Jun 2024
Novavax submits application to EMA for updated protein-based 2024-2025 formula COVID-19 vaccine
24 June 2024 - Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3
Novavax today announced that it has filed for a type II variation of existing marketing authorisation with the EMA for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
